Details of Drug | MecDDI

Drug General Information (ID: D1776)
Drug Name		Dimercaprol
Drug Type		Small molecule
Drug Synonymous		DIMERCAPROL\|2,3-Dimercapto-1-propanol\|59-52-9\|2,3-Dimercaptopropanol\|Dithioglycerine\|Dicaptol\|Sulfactin\|2,3-Dithiopropanol\|dimercaptopropanol\|British Anti-Lewisite\|1,2-Dithioglycerol\|Dimersol\|Antoxol\|Panobal\|British antilewisite\|Dimercaprolum\|1-Propanol, 2,3-dimercapto-\|BAL in Oil\|2,3-bis(sulfanyl)propan-1-ol\|1,2-Dimercapto-3-propanol\|Dimercaprol propanol\|Dithioglycerol\|2,3-Dimercaptol-1-propanol\|Usaf me-1\|3-Hydroxy-1,2-propanedithiol\|BAL\|2,3-Dimercaptopropan-1-ol\|alpha,beta-Dithioglycerol\|Dimerkaprol\|2,3-Mercaptopropanol\|Glycerol, 1,2-dithio-\|2,3-Mercaptopropan-1-ol\|NSC 4646\|2,3-disulfanylpropan-1-ol\|NSC 39515\|1-Propanol, 2,3-dimercapto\|CHEBI:64198\|Dimercaptol\|2,3-dimercapto-propan-1-ol\|.alpha.,.beta.-Dithioglycerol\|NSC4646\|NSC-4646\|Glycerol,2-dithio-\|MFCD00004864\|NSC-39515\|2,3-Dimercapto-1-propanol; Dithioglycerol\|WLN: SH1YSH1Q\|1-Propanol,3-dimercapto-\|Sulfactin (VAN)\|Dimerkaprol [Czech]\|Dimercaprolo [DCIT]\|Dithioglycerol (VAN)\|Dimercaprolo\|Dimercaptopropanol (VAN)\|DMP (VAN)\|Dimercaprolum [INN-Latin]\|2,3-Dimercapro\|NSC16865\|CCRIS 3616\|HSDB 4004\|EINECS 200-433-7\|BRN 1732058\|dithiopropanol\|AI3-61820\|Anti-Lewisite\|Dimercaprol [USP:INN:BAN:JAN]\|Spectrum_001965\|2, 3-dimercaptopropanol\|2,3-dithiopropan-1-ol\|Spectrum2_001218\|Spectrum4_001275\|Spectrum5_001622\|BAL (TN)\|CHEMBL1597\|DSSTox_CID_20461\|DSSTox_RID_79496\|DSSTox_GSID_40461\|SCHEMBL15969\|KBioGR_001890\|KBioSS_002524\|2,3 -dimercapto-1-propanol\|2,3,-dimercapto-1-propanol\|4-01-00-02770 (Beilstein Handbook Reference)\|DivK1c_000997\|SPBio_001036\|2,3-Disulfanyl-1-propanol #\|Dimercaprol (JP17/USP/INN)\|DTXSID5040461\|HMS503G15\|KBio1_000997\|KBio2_002516\|KBio2_005084\|KBio2_007652\|NINDS_000997\|Pharmakon1600-01500252\|BCP18145\|HY-B1285\|NSC39515\|Tox21_110014\|BDBM50103608\|CCG-39156\|NSC760094\|s4446\|AKOS015895110\|DB06782\|NSC-760094\|CAS-59-52-9\|IDI1_000997\|NCGC00013216-01\|NCGC00344527-01\|LS-12962\|NCI60_001345\|SBI-0051351.P002\|DB-053404\|CS-0013059\|D0621\|FT-0625021\|C02924\|D00167\|D89691\|AB00051971_02\|004D864\|2,3-Dimercapto-1-propanol, >=98% (iodometric)\|Q413968\|SR-05000001839\|SR-05000001839-1\|W-105317 Click to Show/Hide
Disease Class		NE6Z: Unspecific substance harmful effect
Therapeutic Class		Antidotes
Structure
Structure		3D Structure				2D Structure
Formula		C3H8OS2
InChI		1S/C3H8OS2/c4-1-3(6)2-5/h3-6H,1-2H2
InChIKey		WQABCVAJNWAXTE-UHFFFAOYSA-N
Canonical SMILES		C(C(CS)S)O
External Link
		Pubchem ID		3080
		CAS Number		CAS 59-52-9
		CHEBI ID		CHEBI:64198
		TTD ID		D0X2IE

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM007 Pharmacodynamic antagonistic effects BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Dimercaprol
Pharmacodynamic antagonistic effects
					Attenuated pharmacological effects (Unspecific)																																																																Drug Num: 15
Drug ID															Drug Name															Formula															Pubchem ID															Severity Level															Interaction Detail													REF
D0647															Ferric carboxymaltose															C24H44FeO25-															86278165															Major															Inter Info													[1], [2], [3]
D0648															Ferric derisomaltose															C18H34FeO16+3															86278348															Major															Inter Info													[1], [2], [3]
D0649															Ferrous fumarate															C4H2FeO4															6433164															Major															Inter Info													[1], [2], [3]
D0650															Ferrous gluconate															C12H22FeO14															23616740															Major															Inter Info													[1], [2], [3]
D0651															Ferrous sulfate anhydrous															FeO4S															24393															Major															Inter Info													[1], [2], [3]
D0652															Ferumoxides															Fe3O4															6432052															Major															Inter Info													[1], [2], [3]
D0653															Ferumoxsil															NA															NA															Major															Inter Info													[1], [2], [3]
D0849															Iron protein succinylate															NA															NA															Major															Inter Info													[1], [2], [3]
D0850															Iron sucrose															C12H29Fe5Na2O23															91663255															Major															Inter Info													[1], [2], [3]
D1456															Selenium															Se															6326970															Major															Inter Info													[1], [2], [3]
D1484															Sodium ferric gluconate complex															C6H11FeNaO7+3															23693558															Major															Inter Info													[1], [2], [3]
D1566															Tetraferric tricitrate decahydrate															C18H32Fe4O31															90478690															Major															Inter Info													[1], [2], [3]
D0654															Ferumoxytol															Fe3H2O4															14789															Major															Inter Info													[1], [2], [3]
D0847															Iron															Fe															23925															Major															Inter Info													[1], [2], [3]
D0848															Iron Dextran															FeH2O4S															105075															Major															Inter Info													[1], [2], [3]

References
1	Desmedt S, Spinewine A, Jadoul M, Henrard S, Wouters D, Dalleur O. Impact of a clinical decision support system for drug dosage in patients with renal failure.?Int J Clin Pharm. 2018;40(5):1225-1233. [PMID: 29785684]
2	Chenoweth MB "Clinical uses of metal-binding drugs." Clin Pharmacol Ther 9 (1968): 365-87. [PMID: 4984845]
3	Product Information. BAL in Oil (dimercaprol). Becton Dickinson, Franklin Lakes, NJ.